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See related research by De Pascale et al. http://ccforum.com/content/18/3/R90 and related editorial by Garnacho-Montero et al. http://ccforum.com/
content/18/3/157We read with interest the paper by De Pascale and
colleagues [1] and the accompanying editorial [2] on
high-dose tigecycline (TGC) in critically ill patients with
severe infections due to multidrug-resistant bacteria. We
agree that the currently recommended TGC dose
(100 mg loading followed by 50 mg twice daily) may be
largely insufficient for treatment of such infections and
may promote resistance. In line with pharmacological
logic, De Pascale and colleagues showed that increasing
the TGC dose improved clinical outcome without
enhancing toxicity. Interestingly, 25% of the patients
included in their study received continuous renal
replacement therapy. Details of and the distribution of
continuous renal replacement therapy between groups
were not provided.
TGC is a small lipophilic antibiotic with a high distri-
bution volume in critically ill patients [3,4]. The rela-
tively high protein binding of TGC precludes significant
removal by intermittent hemodialysis [4]. Recent investi-
gations suggest significant adsorption of many anti-
microbial drugs on dialysis or extracorporeal membrane
oxygenation membranes [3]. Moreover, the increasing
use of highly adsorptive membranes for continuous
hemo(dia)filtration may dramatically alter the pharmaco-
kinetic behavior of many antibiotics [5,6]. Since this is
particularly true for TGC, higher dose regimens (150 mg
loading followed by 100 mg twice daily) in patients
undergoing continuous renal replacement therapy and
extracorporeal membrane oxygenation have been pro-
posed [6].* Correspondence: Patrick.Honore@uzbrussel.be
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unless otherwise stated.De Pascale and colleagues are right to state that more phar-
macokinetic investigation is needed before high-dose TGC
can be recommended for treatment of multidrug-resistant
bacterial infections [1]. We strongly suggest pursuing such
research also in the growing cohort of critically ill patients
treated with extracorporeal techniques equipped with sophis-
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